1. Home
  2. STIM vs AGEN Comparison

STIM vs AGEN Comparison

Compare STIM & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

HOLD

Current Price

$1.34

Market Cap

105.5M

Sector

Health Care

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.30

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STIM
AGEN
Founded
2003
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.5M
126.2M
IPO Year
2018
1999

Fundamental Metrics

Financial Performance
Metric
STIM
AGEN
Price
$1.34
$3.30
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$7.00
$14.50
AVG Volume (30 Days)
2.4M
410.2K
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.37
Revenue
$52,776,000.00
$42,877,086.00
Revenue This Year
$101.67
$5.19
Revenue Next Year
$10.87
$68.25
P/E Ratio
N/A
$9.12
Revenue Growth
N/A
89.95
52 Week Low
$1.20
$1.38
52 Week High
$5.91
$7.34

Technical Indicators

Market Signals
Indicator
STIM
AGEN
Relative Strength Index (RSI) 41.37 53.66
Support Level $1.26 $2.90
Resistance Level $2.13 $4.72
Average True Range (ATR) 0.17 0.18
MACD -0.02 0.06
Stochastic Oscillator 12.93 85.48

Price Performance

Historical Comparison
STIM
AGEN

About STIM Neuronetics Inc.

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: